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 Abstract 
Objective: To investigate the initial termination rate of status epilepticus (SE) in a large 
observational study, and to explore associated variables. 
Methods: Data of adults treated for SE were collected prospectively in centers in Germany, 
Austria, and Switzerland, during 4.5 years. Incident episodes of 1,049 patients were analyzed 
using uni- and multivariate statistics to determine factors predicting cessation of SE within 1 
hour (for generalized convulsive SE, GCSE) and 12 hours (for non-GCSE) of initiating 
treatment. 
Results: Median age at SE onset was 70 years; most frequent etiologies were remote (32%) 
and acute (31%). GCSE was documented in 43%. Median latency between SE onset and first 
treatment was 30 minutes in GCSE and 150 minutes in non-GCSE. The first intravenous 
compound was a benzodiazepine in 86% in GCSE, and 73% in non-GCSE. Bolus doses of the 
first treatment step were lower than recommended by current guidelines in 76% of the GCSE 
patients and 78% of the non-GCSE patients. In 319 GCSE patients (70%), SE was ongoing 1 
hour after initiating treatment, and in 342 non-GCSE patients (58%) 12 hours after initiating 
treatment. Multivariate Cox regression demonstrated that the use of benzodiazepines as 
first treatment step, and a higher cumulative dose of anticonvulsants within the first period 
of treatment were associated with shorter time to cessation of SE for both groups. 
Interpretation: In clinical practice, treatment guidelines were not followed in a substantial 
proportion of patients. This under-dosing correlated with lack of cessation of SE. Our data 
suggest that sufficiently dosed benzodiazepines should be used as first treatment step. 
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 Introduction 
Evidence regarding status epilepticus (SE) treatment, one of the most frequent neurological 
emergencies associated with increased morbidity and mortality, is still scarce. There are only 
few large randomized controlled trials (RCTs) fulfilling criteria of Class-1 evidence, all 
focusing on the first treatment step.1-4 All studies were restricted to generalized convulsive 
SE forms, and three of them1-3 exclusively investigated the effect of pre-hospital treatment. 
Those studies reported treatment success as high as 84% following initial administration of 
pharmacological agents. Real world data, however, suggest that termination rates are lower 
in clinical practice.5,6 With the exception of the Veterans Affairs Study4 and the ongoing 
ESET-Trial (ClinicalTrials.gov Identifier: NCT01960075), both from the USA, prospective 
controlled trials of in-hospital treatment of established SE and outcome have not been 
conducted. Furthermore, data on how guidelines based on these prospective trials have 
been implemented in clinical practice are limited, especially for Europe.  
Therefore, a working group of centers from German-speaking countries established a 
prospective registry for patients treated for SE, with the acronym SENSE (Sustained Effort 
Network for treatment of Status Epilepticus).7,8 It includes data on all treatment stages 
reflecting clinical practice, which were evaluated to determine predictors of cessation of SE 
within the first hour (for GCSE) and initial 12 hours (for non-GCSE) of treatment. 
 
Methods 
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 The methods and design of the SENSE registry have been published elsewhere.7,8 In brief, 
eight centers with special expertise in SE treatment in German-speaking countries 
participated and recruited patients: Germany: Epilepsy Centre University Marburg, 
University Hospital Schleswig-Holstein Campus Kiel, Klinikum Osnabrück, Krankenhaus 
Barmherzige Brüder Regensburg; Austria: Christian-Doppler-Klinik, Universitätsklinikum der 
Paracelsus Medizinischen Universität Salzburg, Department of Neurology, Innsbruck Medical 
University; Switzerland: University Hospital Basel, University Hospital Lausanne (the only 
French-speaking site). The study was approved by the appropriate local ethics committees 
and registered at the German Clinical Trials Register (DRKS00000725). The Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) guidelines9 were followed.  
SE was operationally defined as seizure duration of five minutes or longer, or consecutive 
seizures without returning to baseline for more than five minutes, or in comatose patients 
who fulfilled the electroencephalogram (EEG) criteria for non-convulsive SE as defined by 
Beniczky et al.10 Patients with status-like phenomena owing to hypoxic brain injury, and 
patients under the age of 16 years were excluded. 
We prospectively documented the following variables: demographics, health-related 
parameters, including SE etiology and comorbidities unrelated to it, SE onset, SE semiology, 
treatment, and outcome. We used the modified Rankin scale (mRS)11,12 for global 
assessment of health before SE onset and at hospital discharge, and the status epilepticus 
severity score (STESS).13 Patients who experienced generalized convulsive semiology during 
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 the course of SE were considered as generalized convulsive SE (GCSE) patients. All other 
patients were considered as non-GCSE patients.  
In many guidelines, refractoriness of SE is defined as ongoing SE after administration of an 
adequate dose of a benzodiazepine followed by an adequate dose of a non-benzodiazepine 
anticonvulsant drug. In clinical practice, SE treatment frequently does not follow guidelines, 
but consists of the administration of multiple relatively low doses of one or more 
benzodiazepines and non-benzodiazepine intravenous anticonvulsants.5,14 Frequently, two 
or more agents are administered at the same time, or after a very brief interval. If a second 
compound is used before the previous one has had adequate time to penetrate the blood-
brain barrier, efficacy of the first compound will be underestimated. Thus, treatment success 
cannot easily relate to individual treatment steps in clinical practice.  
To assess the factors contributing to the success of the first phase of treatment, we defined 
‘first steps treatment success’ for GCSE patients as cessation of SE within the first hour after 
treatment initiation. For non-GCSE patients, we chose a prolonged time frame of 12 hours 
instead: this should account for the fact that in several instances of non-convulsive or focal 
motor SE a less aggressive approach of treatment may be appropriate.15,16 In addition, in 
non-motor SE, determining treatment success at night is not possible because continuous 
EEG monitoring is not routinely available in many European centers, or is restricted to 
patients with super-refractory SE.  
Statistical analysis was performed with IBM SPSS Version 25 (Chicago, Illinois, USA). For 
univariate analysis of categorical data, chi-square test and Fisher's exact test were used. 
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 Interval scaled, or ordinal scaled data were analyzed using Mann–Whitney U test 
(comparison of two groups), or Kruskal–Wallis test (comparison of three or more groups).  
To determine the contribution of individual factors to the success of the first treatment step, 
we used multivariate, stepwise (backward) Cox regression (p=0.05 for inclusion and 
exclusion). Time to SE cessation was chosen as dependent variable, with censoring of the 
time at one hour (GCSE patients), respectively 12 hours (non-GCSE patients) after first 
treatment. Patients who died within the first hour (GCSE patients), respectively 12 hours 
(non-GCSE patients) of treatment time, were considered as ongoing SE for this analysis. The 
following variables were considered for the multivariate analysis: age, gender, presence of 
acute etiology, mRS before onset, STESS, latency to first treatment, use of benzodiazepines 
as first step, and cumulative standardized dose of anticonvulsant agents (including 
benzodiazepines) per kg bodyweight used within the first 30 minutes (GCSE patients), 
respectively 60 minutes (non-GCSE patients). For standardization, we divided the bolus dose 
actually administered by the bolus dose recommended by the treatment guidelines of the 
German, Austrian and Swiss scientific societies16 for SE in adults and multiplied the result by 
100. If the guidelines recommended a bolus dose range, the mean of upper and lower limit 
was considered as recommended for calculation purposes. Only patients for whom latencies 
and bolus doses could be determined with sufficient validity and precision were included in 
the multivariate analysis. 
 
Results 
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 Between January 2011 and June 2015, 1,049 patients with 1,179 episodes of SE were 
enrolled in SENSE. For our analysis, only the first episode of each patient was included. The 
clinical characteristics (i.e., demographics, etiology, semiology, comorbidities) are shown in 
tables 1 and 2. 
Median age at SE onset was 70 years (interquartile range [IQR], 54−80 years), and 51% of the 
patients were women. Most frequent etiologies were remote symptomatic, closely followed 
by acute symptomatic factors, or a combination of both. Almost half of the patients had 
generalized tonic-clonic seizure symptoms during the SE. Less than half of the patients had 
no impairment of their everyday life by signs or symptoms of a pre-existing health disorder, 
as signified by a mRS of 0−2.    
SE treatment was initiated within 30 minutes in 221 of 457 GCSE patients (48%), and in 112 
of 592 non-GCSE patients (19%). Median latency between SE onset and treatment was 30 
minutes (IQR, 25−240) for the GCSE patients, and 150 minutes (IQR, 45-420) for the non-
GCSE patients. The first treatment step, most frequently one or a combination of several 
benzodiazepines, was successful in 98 GCSE patients (21%), and 93 non-GCSE patients (16%), 
details are included in tables 3 and 4. In patients with GCSE, levetiracetam (LEV) was used as 
first treatment step only in 28 cases (6%), whereas in non-GCSE, 130 patients (22%) received 
LEV as first treatment step. The second treatment step was administered in 359 GCSE 
patients and in 499 non-GCSE patients after a median latency of 30 minutes from start of 
administration of the first drug, and was successful in 46% of the GCSE patients, and in 38% 
of the non-GCSE patients (thus, the total success rate of the first two steps was 58% for the 
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 GCSE patients, and 47% for the non-GCSE patients) (supplemental table 1). LEV was most 
frequently used (227 GCSE patients and 307 non-GCSE patients), followed by valproate (40 
GCSE patients and 71 non-GCSE patients).  
Treatment lasted between a few minutes and more than 55 days (median, 272 minutes; IQR, 
55−2,457 minutes). Bolus doses of intravenous compounds were considerably lower than 
recommended in current treatment guidelines (supplemental table 2). Bolus doses of 
lorazepam were significantly lower than recommended both in refractory GCSE (p<0.05) and 
refractory non-GCSE (p<0.01) patients. The other individual agents did not differ significantly 
between groups. However, cumulative standardized bolus doses applied in the first 0.5, 2, 
and 12 hours of treatment, respectively, were significantly lower in refractory compared to 
non-refractory GCSE patients, as well as in refractory non-GCSE patients compared to non-
refractory non-GCSE patients (p<0.001). A significantly (p<0.001) higher proportion of non-
GCSE patients with ongoing SE was intubated during treatment.  
In 439 GCSE patients (96%) and 540 non-GCSE patients (91%), SE ceased during the in-
hospital stay: within the first 0.5 hours after treatment initiation in 97 GCSE patients (24%), 
and 73 non-GCSE patients (15%); after 2 hours in an additional 91 GCSE patients (20%) and 
78 non-GCSE patients (13%); and after 12 hours in an additional 98 GCSE patients (21%) and 
98 non-GCSE patients (17%). In-hospital mortality was 9% (43 patients) for GCSE and 19% 
(114 patients) for non-GCSE (see table 5). Both refractory GCSE patients and non-GCSE 
patients  had a higher chance of worsening in mRS at discharge compared to non-refractory 
patients. 
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 Compared to GCSE patients with ongoing SE after 1 hour of treatment, those GCSE patients 
treated successfully were younger (p<0.01), and they had a shorter treatment latency 
(p<0.001), a higher rate of benzodiazepines as first treatment step (p<0.001), a shorter 
interval between the first two treatment steps (p<0.001), and a higher standardized 
cumulative dose of anticonvulsants within the first 30 minutes of treatment (p<0.001). In 
non-GCSE patients, subjects treated successfully within the first 12 hours were younger 
(p<0.001), had lower STESS, received more often benzodiazepines as first step treatment 
(p<0.001), had a shorter interval between the first two treatment steps (p<0.001), and a 
higher standardized cumulative dose of anticonvulsants (p<0.001); treatment latency failed 
to reach significance (p=0.059). There was no significant difference regarding etiology 
between refractory and non-refractory patients in both SE subgroups.  
Multivariate analysis (supplemental table 3) showed that in GCSE patients, younger age 
(hazard ratio (HR) 0.89 – 95% confidence interval (CI) 0.82-0.97, p=0.01), lower mRS before 
SE onset (HR 0.89 – 95%CI 0.8-0.99, p=0.05), the application of a benzodiazepine as initial 
drug (HR 9.62 – 95%CI 1.34-69.3, p=0.04), a higher cumulative dose of anticonvulsant agents 
given within the first 30 minutes of treatment (HR 1.02 - 95%CI1.01-1.03, p=0.002), and 
shorter latency from SE onset to treatment initiation (HR 0.89 – 95%CI 0.82-0.97, p=0.04) 
independently predicted a shorter time to cessation of SE within the first hour of treatment. 
In non-GCSE patients, significant factors associated with a shorter time to SE cessation within 
the first 12 hours were lower STESS (HR 0.8 95%CI 0.73-0.88, p<0.001), lower number of 
comorbidities (HR 0.89 – 95%CI 0.81-0.97, p=0.004), use of a benzodiazepine as first drug 
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 (HR 1.96 – 95%CI 1.36-2.84, p<0.001), and higher cumulative standardized drug dose within 
the first 60 minutes (HR 1.01 – 95%CI 1.01-1.02, p=0.002).  
 
Discussion 
This study relies on a large prospective observational adult SE registry, reflecting situations 
occurring in clinical practice in several European hospitals. It shows that in the vast majority 
of patients, SE ceases during the hospital stay. However, the success rate of the first 
treatment steps – regardless of the compound used – was much lower than reported in 
randomized controlled studies. In addition, bolus doses in most cases tended to be lower 
than recommended by guidelines. Moreover, in 15% of patients, benzodiazepines were not 
used as first-line agents. The use of benzodiazepines as first treatment step, and the 
cumulative dose of all agents applied within the first 30-60 minutes of treatment had 
significant influence on SE cessation within the first hours of treatment, independently from 
other outcome predictors. This holds true both for patients with GCSE and with non-GCSE. 
SE ceased within the first 30 minutes in only 16% and in 51% of patients within 12 hours 
following treatment initiation. Globally, this appears to be much lower than reported in 
randomized trials, where treatment responses within the first hour ranged between 
76−81%17, 44−65%4, 43−59%1, 63−73%3, and 74−84%2. Interestingly, the only randomized 
study that included a placebo arm reported a success rate of 16%,1 which is similar to our 
findings. However, these studies essentially focused on generalized convulsive SE with a 
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 fixed treatment protocol, allowing observation of the benzodiazepine effect before 
administering a subsequent compound.  
This differs from common clinical practice outside an RCT setting, where intravenous 
antiepileptic drugs (AEDs) are often given virtually at the same time of the first treatment 
step.5,6,18,19 For example, in a recent multicenter observational study in European and US 
centers, 156/177 (88%) adult patients received a second anticonvulsant after a 
benzodiazepine, and the latter was underdosed in 59% of cases, as compared with existing 
guidelines.5 In addition, our cohort included, on average, considerably older patients, with a 
higher rate of severe comorbidities compared with the randomized trials. Furthermore, in 
the present study, as in other observational population-based20,21 or hospital cohorts,5,6 only 
a proportion of around 50% had generalized convulsive SE, as opposed to RCTs specifically 
recruiting patients with this SE type. Concluding that benzodiazepines were efficacious in 
only 12% of cases (which is even lower than placebo in the study by Alldredge and 
colleagues1) would therefore be misleading. 
In contrast with the low success rate of the first treatment step, more than 90% of SE ceased 
during in-hospital stay. At first glance, it seems surprising that SE was eventually controlled 
in almost all patients despite the initial delays and underdosing of anticonvulsants. Several 
considerations are important: firstly, SE control does not necessarily result in a favorable 
outcome in terms of mRS or quality of life in these patients − ongoing SE may result in 
survival with new impairments; secondly, patients in the study were not left without 
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 treatment, but received many different anticonvulsants, which may have needed time to 
reach maximum efficacy.  
Ultimately, there may have been good clinical reasons to avoid strict adherence to guidelines 
for the treatment of generalized convulsive SE. This is most likely in multi-morbid, frail, and 
elderly patients with non-convulsive SE, in whom therapeutic coma using intravenous 
anesthetics is frequently avoided, due to the risks of artificial ventilation and cardiovascular 
depression inherent to this therapy, which is associated with increased mortality, infection 
rate,22-24 22-24 and length of hospital stay.22-24   
Benzodiazepines were used as a first-line agent in 81% of the events, while LEV (15%) or 
other non-benzodiazepine anticonvulsants were used as alternatives. This is consistent with 
several observational and registry studies showing that the majority of patients do receive 
benzodiazepines as first-line (90%;25 93%;26 97%6). A Swiss study found a rate of 16% 
deviation from the recommended sequence ‘benzodiazepine -> intravenous non-
benzodiazepine anticonvulsant’, which is comparable with our results.14 A recent study of 
emergency treatment of out-of-hospital SE27 showed that early treatment with a 
benzodiazepine depended on the SE semiology. Patients with non-convulsive SE were at risk 
of not receiving early benzodiazepine treatment in comparison with those with convulsive 
SE. Thus, a correlation between prominence of motor symptoms and subsequent SE 
treatment could partly explain our results. 
Our findings strongly suggest that the initial administration of a benzodiazepine versus a 
non-benzodiazepine intravenous anticonvulsant predicts earlier SE cessation. This supports 
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 current treatment guidelines16,28,29 and the results from the pivotal trials that these 
guidelines are based on.1,3,4 For example, the ‘Veterans Affairs trial’4 provided evidence that 
lorazepam (0.1 mg/kg, 64.9%) was significantly (p<0.001) more effective in controlling overt 
convulsive SE than phenytoin (18 mg/kg, 43.6%).  
There is evidence that benzodiazepines are more effective than placebo,1 that lorazepam is 
better than diazepam,30 and that intramuscular midazolam is superior to intravenous 
lorazepam when administered rapidly en route to the hospital before establishing an 
intravenous access.3 Results regarding the relative efficacy of LEV, the non-benzodiazepine 
intravenous anticonvulsant drug most frequently used as first-line treatment instead of a 
benzodiazepine in our registry, are variable. The simultaneous application of 2.5 g LEV with 1 
mg clonazepam had no additional effect on the cessation rate of generalized convulsive SE 
after 10 minutes compared with clonazepam alone,2 and a retrospective study suggested 
that LEV was less effective than valproic acid as second-line therapy.31 Our findings suggest 
that LEV may be less efficacious than benzodiazepines as first-line drug.   
A higher cumulative weight-adjusted dose of anticonvulsants was associated with a higher 
likelihood of SE cessation within the first hour in GCSE patients, and within the first 12 hours 
in non-GCSE patients, in a dose-related manner, indicating that underdosing is a risk factor 
for non-cessation of SE. There is evidence from RCTs that the application of a second dose of 
anticonvulsants is effective in the majority of patients who continue to seize after the first-
line dose.1,3,17 Accordingly, guidelines recommend administering an additional dose of 
benzodiazepine or other anticonvulsant if SE is not initially controlled.15,16,29 This 
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 recommendation is also supported by our data. On the other hand, overtreatment may put 
patients at risk for harmful adverse events, since it is associated with a higher need for 
intubation and a longer duration of hospitalization.32 This risk needs to be weighted against 
the risks of ongoing SE, associated with a higher proportion of worsening in mRS in 
refractory patients in our cohort.  
Our data do not suggest superiority or inferiority of one particular substance compared to 
others. Analysis of the relative value of different benzodiazepines shows no significant 
difference between lorazepam, midazolam, diazepam or a combination when used as first 
substance (figure 1). In addition, overall success rates of non-benzodiazepine substances 
used in 50 or more patients were all between 38% and 44%8.   
One could assume that a higher cumulative dose of benzodiazepines, non-benzodiazepine 
anticonvulsants, or both in the early phase of treatment carries a higher risk of significant 
sedation and respiratory insufficiency as side-effect. However, this putative effect did not 
result in a higher proportion of intubation for airway protection in both GCSE and non-GCSE 
patients with SE cessation within one hour (resp. 12 hours) despite a significantly higher 
cumulative dose of both benzodiazepines and other anticonvulsants. Moreover, only a very 
small minority of patients with SE cessation within the first 12 hours were aggressively 
treated with intentional anesthesia for SE treatment. Our findings are supported by data 
from a large placebo-controlled study of ambulance-based treatment of convulsive SE 1that 
showed that the risk of respiratory insufficiency in the placebo arm was much higher than in 
the treatment arms (lorazepam and diazepam). 
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 Latency from SE onset to treatment showed significant contribution to the risk of ongoing SE 
in GCSE patients. In non-GCSE patients, significance was missed in univariate analysis 
(p=0.06) and in multivariate analysis (p=0.28). Patients who received first treatment very 
early were very likely to receive benzodiazepine treatment as first step and possibly in a 
higher dose. Therefore, the contribution of early treatment could have been masked. Age 
was a significant predictor of refractoriness in multivariate analysis only for GCSE patients. 
For non-GCSE patients, significance was missed. This could be explained by the generally 
older age of the non-GCSE patients and thus the smaller interquartile range that may have 
masked the effect. The same effect may apply for the mRs before SE onset which also 
reached significance only for the GCSE group. 
The number of comorbidities was a significant predictor of time to SE cessation only in the 
non-GCSE group. In this group, the median duration of in-patient treatment was higher. In 
our protocol, treatment-associated complications or hospital-associated disorders such as 
pneumonia or other infections were documented as comorbidities. Therefore, the larger 
difference of duration of treatment between the refractory and the non-refractory non-
GCSE patients may be the underlying confounder for reaching significance.  
STESS was a significant predictor of non-cessation of SE only for the non-GCSE group. This 
group contains patients with non-convulsive SE (NCSE) in coma as well as patients with focal 
motor SE or dyscognitive SE. Patients with NCSE in coma score 2 points in the STESS category 
‘worst seizure type’, and are more likely to be refractory33, whereas non-GCSE patients 
without coma score 0 points for ‘worst seizure type’ in STESS. In contrast to that, all GCSE 
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 patients score 1 point in this STESS category, resulting in a smaller interquartile range. 
Therefore, STESS - which was developed to predict mortality and not refractoriness13 - seems 
to be able to predict refractoriness only in the more heterogenous group of non-GCSE 
patients. 
 
Non-GCSE patients treated in German centers had a higher risk of refractoriness in 
univariate analysis. In German centers, patients tended to be older. Older age is associated 
with infavorable outcome34. In addition, in German centers lorazepam was used much more 
frequently. A retrospective analysis of SE data from four centers5 could demonstrate that the 
use of lorazepam was associated with an increased risk of refractoriness, most likely as a 
consequence of underdosing. 
 
This study has several limitations. Firstly, contributions of different centers in terms of 
patient numbers were fairly divergent, decreasing the cohort homogeneity, and potentially 
impacting generalizability. In addition, there was no independent comparison between 
hospital coding of SE data and database entry. It is possible that this led to reporting bias, 
especially under-ascertainment. In addition, treatment was neither randomized nor 
controlled. Therefore, correlations between treatment data and outcome must be 
interpreted with caution. Moreover, cases excluded from multivariate analysis were not 
randomly distributed (see supplementary table 1). Thus, the results may have been biased 
by cases with missing information. Continuous EEG (cEEG) was not available for most of the 
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 patients. It should be stressed that this is suboptimal care. Academic societies and patient 
organisations should press for separate reimbursement of cEEG in SE patients. This would 
allow European hospitals to establish the standards of care already available in most U.S. 
centers. 
On the other hand, our database documents ‘real life’ treatment in clinical practice, in 
centers with special interest in SE treatment, and the previously published, standardized 
ascertainment protocol should limit marked internal bias.7 The number of patients included 
was clearly higher than in comparable registries or trials. The sample size and heterogeneity, 
based on cohorts from three countries, from both university hospitals and non-academic 
hospitals, allow thorough statistical analysis, and support generalizability.  
Current guidelines on the treatment of SE are based on studies almost exclusively 
investigating patients with generalized convulsive SE, or on small and uncontrolled studies. 
We hope that our findings will help improve adherence to current treatment guidelines on 
the use of benzodiazepines and the use of sufficiently high doses in the first steps of therapy, 
and thereby improve the quality of patient care. Moreover, the registry may prove an 
important tool for generating hypotheses regarding treatment and outcome of SE, and may 
help design conclusive therapy trials. 
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 Figure Legend 
Kaplan-Meier analysis of cumulative patients with ongoing status epilepticus (SE). Time from 
treatment initiation was censored at 1 hour for patients with generalized convulsive SE 
(GCSE) (a) and at 12 hours for patients with non-GCSE (b). Patients who died within the 
period were considered as ongoing SE for this analysis.  
CLZP, clonazepam; comb, combination of two or more benzodiazepines as first treatment 
step; DZP, diazepam; LEV, levetiracetam; LZP, lorazepam; MDZ, midazolam.   
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 Table 1: Characteristics of patients with GCSE 
  All patients with GCSE 
(n=457) 
GCSE – cessation 
within 60 minutes 
(n=138) 
GCSE – non-cessation 
within 60 minutes 
(n=319) 
Country Germany 199 57 (29%) 142 (71%) 
 Austria 98 32 (33%) 66 (67%) 
 Switzerland 160 49 (31%) 111 (69%) 
Age (years) Median (range) 65 (18-100) 58 (19-97) 67 (18-100)** 
 IQR 49-78 41-75 54-79 
Gender Female 203 53 (26%) 150 (74%) 
 Male 254 85 (34%) 169 (66%) 
mRS before 
onset 
0-2 185 70 (38%) 115 (62%) * 
 3 112 33 (30%) 79 (70%) 
 4 95 21 (22%) 74 (78%) 
 5 65 14 (22%) 51 (79%) 
Comorbidities 
(number) 
Median (IQR) 2 (1-3) 2 (1-3) 2 (1-3) 
Pre-existing 
epilepsy 
yes 227 77 (34%) 150 (66%) 
Etiology Acute symptomatic 
only 
151 42 (28%) 109 (72%) 
 Acute on remote 52 16 (31%) 36 (69%) 
 Remote 
symptomatic only 
141 56 (40%) 85 (60%)  
 Progressive 57 16 (28%) 41 (72%) 
 Unknown/other 56 8 (14%) 48 (86%) 
STESS Median (IQR) 3 (3-4) 3 (2-4) 3 (2-4) 
 STESS ≤2 128 39 (31%) 89 (69%) 
SE, status epilepticus; GCSE, generalized convulsive SE; IQR, interquartile range (25th-75th quartile); 
mRS, modified Rankin Scale; STESS, SE severity score;  
*p<0.05; **p<0.01; ***p<0.001 for comparison between cessation group and non-cessation group 
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 Table 2: Characteristics of patients with non-GCSE 
  All patients with 
non-GCSE 
(n=592) 
Non-GCSE – 
cessation within 12 
hours (n=250) 
Non-GCSE – non-
cessation within 12 
hours (n=342) 
Country Germany 278 80 (29%) 198 (71%) *** 
 Austria 116 70 (60%) 46 (40%) 
 Switzerland 198 100 (51%) 98 (49%) 
Age (years) Median (range) 72 (18-100) 68.5 (20-100)  74 (18-94)*** 
 IQR 59-81 55-79 64-83 
Gender Female 334 133 (40%) 201 (60%) 
 Male 258 117 (45%) 141 (55%) 
mRS before 
onset 
0-2 267 125 (47%) 142 (53%) 
 3 144 56 (39%) 88 (61%) 
 4 118 48 (41%) 70 (59%) 
 5 63 21 (33%) 42 (67%) 
Comorbidities 
(number) 
Median (IQR) 3 (2-4) 2 (1-4) 3 (2-4)** 
Pre-existing 
epilepsy 
yes 258 112 (43%) 146 (57%) 
Etiology Acute 
symptomatic only 
179 82 (45%) 97 (55%) 
 Acute on remote 48 16 (33%) 32 (67%) 
 Remote 
symptomatic only 
193 77 (40%) 116 (60%) 
 Progressive 106 48 (45%) 58 (55%) 
 Unknown/other 66 27 (41%) 39 (60% 
STESS Median (IQR) 2 (2-3) 2 (1-3) 2 (2-4)*** 
 STESS ≤2 325 159 (49%) 166 (51%)*** 
SE, status epilepticus; GCSE, generalized convulsive SE; IQR, interquartile range (25th-75th quartile); 
mRS, modified Rankin Scale; STESS, SE severity score;  
*p<0.05; **p<0.01; ***p<0.001 for comparison between cessation group and non-cessation group 
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 Table 3: First treatment step in patients with GCSE 
  All patients 
with GCSE 
(n=457) 
GCSE – cessation 
within 60 
minutes (n=138) 
GCSE – non-
cessation within 60 
minutes 
(n=319) 
Latency from 
SE onset to 
first 
treatment 
step (min) 
Median (range; 
IQR) 
30 (5-4970; 20-
90) 
(425 valid 
cases) 
25 (5-1220; 15-
60) 
(136 valid cases) 
20 (5-4970; 20-
120)*** 
(288 valid cases) 
 ≤ 30 min 221 86 (39%) 135 (61%) 
 31-120 min 121 35 (29%) 86 (71%) 
 2 h – 6 h 48 11 (23%) 37 (77%) 
 6 h – 24 h 57 6 (11%) 51 (89%) 
 >24 h 10 0 10 
First step LZP 120 35 (29%) 85 (71%) 
 DZP 24 11 (46%) 13 (54%) 
 CLZ 87 26 (30%) 61 (70%) 
 MDZ 59 23 (39%) 36 (61%) 
 Combined BZD 122 39 (32%) 83 (68%) 
 LEV 28 1 (4%) 27 (96%) 
 Other 17 3 (18%) 14 (82%) 
BZD as first 
line therapy 
Yes 412 134 (33%) 278 (67%) *** 
First agent 
underdosed 
Yes 348 107 (31%) 241 (69%) 
First step 
successful 
Yes 98 (21%)   
SE, status epilepticus; GCSE, generalized convulsive SE; BZD, benzodiazepines; CLZ, clonazepam; 
DZP=diazepam; h, hours; IQR, interquartile range (25th−75th quartile); LEV, levetiracetam; LZP, 
lorazepam; MDZ=midazolam; min, minutes;.Underdosed: bolus dose <70% of recommended bolus 
dose. Valid patients: patients where the documentation of application time resp. bolus dose was 
precisely documented.  
***p<0.001 for comparison between cessation group and non-cessation group 
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 Table 4: First treatment step in patients with non-GCSE 
  All patients with 
non-GCSE 
(n=592) 
Non-GCSE – 
cessation within 12 
hours (n=250) 
Non-GCSE – non-
cessation within 12 
hours (n=342) 
Latency from 
SE onset to 
first 
treatment 
step (min) 
Median (range; 
IQR) 
150 (5-13200; 45-
420) 
(486 valid cases) 
120 (5-10425; 30-
427) 
(246 valid cases) 
180 (5-13200; 60-
420) 
(240 valid cases) 
 ≤ 30 min 112 66 (59%) 46 (41%) *** 
 31-120 min 117 58 (49%) 59 (51%) 
 2 h – 6 h 123 57 (46%) 66 (54%) 
 6 h – 24 h 162 41 (25%) 121 (75%) 
 >24 h 78 28 (36%) 50 (64%) 
First step LZP 198 97 (49%) 101 (51%) 
 DZP 20 9 (45%) 11 (55%) 
 CLZ 124 64 (52%) 60 (58%) 
 MDZ 26 11 (42%) 15 (58%) 
 Combined BZD 66 32 (49%) 32 (51%) 
 LEV 130 33 (25%) 97 (75%) 
 Other 28 4 (14%) 24 (86%) 
BZD as first 
line therapy 
Yes 437 214 (49%) 223 (51%) *** 
First agent 
underdosed 
Yes 467 206 (44%) 261 (56%) 
First step 
successful 
Yes 93 (16%)   
SE, status epilepticus; GCSE, generalized convulsive SE; BZD, benzodiazepines; CLZ, clonazepam; 
DZP=diazepam; h, hours; IQR, interquartile range (25th−75th quartile); LEV, levetiracetam; LZP, 
lorazepam; MDZ=midazolam; min, minutes;.Underdosed: bolus dose <70% of recommended bolus 
dose. Valid patients: patients where the documentation of application time resp. bolus dose was 
precisely documented. 
 ***p<0.001 for comparison between cessation group and non-cessation group 
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 Table 5: Outcome data for patients with GCSE  
  All patients 
with GCSE 
(n=457) 
GCSE – cessation 
within 60 
minutes  
(n=138) 
GCSE – non-
cessation within 
60 minutes 
(n=319) 
Intubation  Yes 108 30 (28%) 78 (72%)  
For airway        
protection 
Yes 74 24 (32%) 50 (68%) 
For SE treatment Yes 34 6 (18%) 28 (82%) 
SE stopped during 
hospital stay 
Yes  439 138 (31%) 301 (69%) 
Treatment duration 
(min) 
Median (IQR) 150 (40-
1265) 
20 (10-40) 540 (153-
2767)*** 
Latency from last 
treatment to SE end 
(min) 
Median (IQR) 40 (10-460) 10 (5-20) 225 (30-1095)*** 
mRS at discharge 0-2 123 59 (48%) 64 (52%) 
 3 111 38 (34%) 73 (66%) 
 4 89 21 (24%) 68 (76%) 
 5 92 18 (20%) 74 (80%) 
 6 (death 
during 
hospital stay) 
43 3 (7%) 40 (93%) ***  
Patients with no 
change of mRS 
 317 118 (37%) 199 (63%) *** 
Duration of hospital 
stay (days) 
Median (IQR) 8 (4-16) 5 (2-9) 10 (5-18)*** 
SE, status epilepticus; GCSE, generalized convulsive SE; NCSE, non-convulsive SE; IQR, interquartile 
range (25th−75th quartile); min, minutes; mRS= modified Rankin Scale; 
***p<0.001 for comparison between cessation group and non-cessation group 
  
 
 
This article is protected by copyright. All rights reserved.
 Table 6: Outcome data for patients with non-GCSE  
  All patients with 
non-GCSE  
(n=592) 
Non-GCSE – 
cessation within 12 
hours (n=250) 
Non-GCSE – non-
cessation within 12 
hours (n=342) 
Intubation  Yes 89 14 (16%) 75 (84%) *** 
For airway        
protection 
Yes 37  7 (19%) 30 (81%) ** 
For SE treatment Yes 52 7 (13%) 45 (87%) 
SE stopped during 
hospital stay 
Yes  540 250 (46%) 290 (54%) 
Treatment duration 
(min) 
Median (IQR) 500 (60-3440) 30 (10-120) 1425 (850-3720)*** 
Latency from last 
treatment to SE end 
(min) 
Median (IQR) 180 (29-1200) 75 (29-202) 3780 (1460-7512)*** 
mRS at discharge 0-2 144 91 (63%) 53 (37%) 
 3 95 53 (56%) 42 (44%) 
 4 142 59 (42%) 83 (58%) 
 5 97 29 (30%) 68 (70%) 
 6 (death 
during 
hospital stay) 
114 18 (16%) 96 (84%) *** 
Patients with no 
change of mRS 
 305 177 (58%) 128 (42%) *** 
Duration of hospital 
stay (days) 
Median (IQR) 11 (5-20) 7 (3-14) 14 (8-24)*** 
SE, status epilepticus; GCSE, generalized convulsive SE; NCSE, non-convulsive SE; IQR, interquartile 
range (25th−75th quartile); min, minutes; mRS= modified Rankin Scale; 
** p<0.01; ***p<0.001 for comparison between cessation group and non-cessation group 
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